Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
SS Innovations International ( (SSII) ) has shared an announcement.
On May 14, 2025, SS Innovations International announced its unaudited financial results for the first quarter of 2025, revealing a record quarterly revenue of $5.1 million, a 40.8% increase from the previous year, driven by higher sales of the SSi Mantra 3 surgical robotic system. The company reported a reduction in net loss and an expansion in gross margin, alongside significant growth in installations and surgeries performed. Following the quarter, SS Innovations uplisted to Nasdaq, marking a step towards global expansion, with plans to seek FDA approval for the SSi Mantra in the U.S. and pursue a CE Mark in the EU, aiming to democratize robotic surgery worldwide.
More about SS Innovations International
SS Innovations International, Inc. is a developer of innovative surgical robotic technologies with a mission to make robotic surgery affordable and accessible globally. The company offers the SSi Mantra surgical robotic system and SSi Mudra surgical instruments, supporting various procedures including robotic cardiac surgery. Headquartered in India, SS Innovations aims to expand its presence worldwide with its advanced and cost-effective solutions.
Average Trading Volume: 29,303
Technical Sentiment Signal: Buy
Current Market Cap: $1.96B
For a thorough assessment of SSII stock, go to TipRanks’ Stock Analysis page.